X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BI 771716 is an antibody fragment-based compound, which is being evaluated in the early-stage clinical trial studies for the treatment of patients with geographic atrophy.
Lead Product(s): BI 771716
Therapeutic Area: Ophthalmology Product Name: BI 771716
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
It is a T cell receptor (TCR) gene therapy, which is being evaluated in preclinical trials for the treatment of patients with KK-LC-1/HLA-A*01-positive cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
CDR404 is an antibody-based, bivalent and bispecific MAGE-A4 T-cell engager (TCE) based on the company's unique M-gager® technology. It is being evaluated in preclinical studies for the treatment of Lung cancer, bladder cancer & Esophageal cancer.
Lead Product(s): CDR404
Therapeutic Area: Oncology Product Name: CDR404
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
BI 771716, developed with technology licensed from CDR-Life, is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
Lead Product(s): BI 771716
Therapeutic Area: Ophthalmology Product Name: BI 771716
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Under the collaboration, the partners will advance CDR-Life’s preclinical antibody fragment-based therapeutic including CDR202, targeting a key pathway in geographic atrophy (GA).
Lead Product(s): CDR202
Therapeutic Area: Ophthalmology Product Name: CDR202
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $487.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2023
Details:
Proceeds from financing will advance CDR404 through potential clinical proof-of-concept readout as well as expansion of the pipeline leveraging M-gager® technology for targeting intracellular antigens positioned to deliver unparalleled specificity and affinity in solid tumors.
Lead Product(s): CDR404
Therapeutic Area: Oncology Product Name: CDR404
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $76.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 13, 2022
Details:
CDR404, a first-in-class dual MAGE-A4 T-cell engager, results from the pre-clinical proof-of-concept, demonstrated that antibody targeting a highly cancer-specific intracellular protein is highly effective in recruiting immune system to specifically eradicate tumour cells.
Lead Product(s): CDR404
Therapeutic Area: Oncology Product Name: CDR404
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.
Lead Product(s): Antibody fragment-based therapeutics
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $494.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
